Plain-English translation of NCT05761366 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new imaging technology called 18F-PSMA PET/CT scan that may help doctors find and identify certain types of cancer more accurately. The scan works by using a special tracer to light up cancer cells in the body. Researchers want to see how well this new imaging approach can detect various cancers, including prostate cancer, colon cancer, liver cancer, and several others.
Current imaging methods sometimes miss cancers or cannot clearly show where they are located. This trial exists to see whether this medication can improve how doctors spot and diagnose these cancers early, which could lead to better treatment outcomes for patients.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive a specialized PET/CT imaging scan using the new tracer medication. During the scan, you will lie still inside a scanner machine while it takes detailed pictures of your body to look for cancer. The entire process typically takes a few hours, and you will be monitored by the medical team throughout to ensure your safety.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Enrollment target
~400 participants
Started
October 2022
Primary completion
October 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xin Cheng, MD
National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and PUMC
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.